Accessibility Menu
Enveric Biosciences logo

Enveric Biosciences(NASDAQ) ENVB

Current Price$1.32
Market Cap$4.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-92%
1 Month+1%
Enveric Biosciences last closing stock price
MetricPriceDate
Last closeUSD 1.342026-07-22
Enveric Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.52%USD 1.322026-07-15
1 month+0.75%USD 1.332026-06-22
3 month-66.67%USD 4.022026-04-23
Year to date-63.09%USD 3.632025-12-31
1 year-92.08%USD 16.922025-07-22
3 year-99.75%USD 525.602023-07-21
5 year-99.99%USD 17,280.002021-07-23
Since inception-100%USD 38,340.002020-12-31

Enveric Biosciences Financials at a Glance

Market Cap

$4.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$8.22M

EPS (TTM)

-$27.35

P/E Ratio

-0.05

Dividend

$0.00

Beta (Volatility)

1.46 (Average)

Price

$1.32

Volume

0

Open

$1.40

Previous Close

$1.32

Daily Range

$1.32 - $1.42

52-Week Range

$1.26 - $17.64

Estimated Earnings Date

Aug 17, 2026

ENVB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Enveric Biosciences

Enveric develops new medicines for mental health and cancer-related conditions. Its drug candidates aim to help people with depression, anxiety, and pain. The company focuses on treatments that do not cause hallucinations, making them accessible for more patients.

Products and Services

  • EVM301 Series: Lead program for mental health, targeting depression and anxiety; preclinical stage; 0% of revenue.
  • EVM401 Series: Non-hallucinogenic drugs for addiction and psychiatric disorders; launched in 2025; 0% of revenue.
  • EVM201 Series: Out-licensed for neuropsychiatric disorders; potential milestone payments; 0% of revenue.
  • EV104: Drug candidate for osteoarthritis pain; 0% of revenue.
  • EV102/EV101: Cream and combination therapy for skin and cancer care; 0% of revenue.

Growth and Expansion

  • Out-licensed EVM201 Series to MycoMedica Life Sciences in Q4 2024 for potential milestone and royalty payments.
  • Signed licensing deals with Aries Science and Technology (July 2024) and Restoration Biologics (February 2025) for cannabinoid-based products.
  • Launched EVM401 Series in February 2025 to expand the drug pipeline.
  • Solicited offers for the PsyAI portfolio in March 2025 to explore licensing or sale opportunities.

What Makes Enveric Stand Out

Enveric uses a proprietary molecular library to develop new mental health drugs. The company focuses on non-hallucinogenic treatments, aiming to fill gaps in psychiatric care. Strategic out-licensing and intellectual property expansion support its business model.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Operating loss was $3 million in Q2 2025, a 32.7% increase in loss compared to Q2 2024.
  • Cash was $2.85 million as of June 30, 2025, up from $2.24 million at year-end 2024.
  • Net cash used in operations was $4.28 million for the first half of 2025, improving approximately 22% from 2024.
  • No debt reported as of June 30, 2025; operations funded by equity offerings.

Bottom Line

Enveric remains a pre-revenue biotech focused on mental health and cancer care innovation. The company relies on partnerships and intellectual property to support its ongoing research and development.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

6

CEO

Joseph Tucker, PhD

Website

www.enveric.com

Headquarters

Cambridge, MA 34103, US

ENVB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-220.99%

Return on Capital

-210.04%

Return on Assets

-148.88%

Earnings Yield

-20.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.68M

Volume

0

Avg. Volume

1.07M

Financials (TTM)

Gross Profit

-$157.07K

Operating Income

-$8.22M

EBITDA

-$8.06M

Operating Cash Flow

-$8.01M

Capital Expenditure

-$4.00

Free Cash Flow

-$8.01M

Cash & ST Invst.

$4.91M

Total Debt

$0.00

Enveric Biosciences Performance Analysis

Enveric Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Enveric Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Enveric Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2,340.28-87.5%
20232023-12-31USD -1,455.53-37.8%
20242024-12-31USD -228.48-84.3%
20252025-12-31USD -36.24-84.1%
Enveric Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3099.9%
Q32025-09-307.1%
Q42025-12-3164.8%
Q12026-03-3171.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$37.24K

+54.0%

Gross Margin

0.00%

N/A

Market Cap

$4.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$822.28K

N/A

Employees

6

N/A

Net Income

-$1.63M

+25.2%

EBITDA

-$1.60M

+24.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.91M

+14.3%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$4.68K

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.49%

N/A

Return on Invested Capital

-1.62%

N/A

Free Cash Flow

-$2.26M

+5.6%

Operating Cash Flow

-$2.26M

+5.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLRXSalarius Pharmaceuticals, Inc.
$0.84+29.23%
INDPIndaptus Therapeutics, Inc.
$2.65+4.96%
SLXNSilexion Therapeutics Ltd.
$2.52+0.40%
ZVSAZyVersa Therapeutics, Inc.
$0.12+1.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About ENVB

What is the current price of Enveric Biosciences?

Enveric Biosciences is trading at $1.32 per share.

What is the 52-week range for Enveric Biosciences?

Over the past 52 weeks, Enveric Biosciences has traded between $1.26 and $17.64.

How much debt does Enveric Biosciences have?

As of the most recent reporting period, Enveric Biosciences reported total debt of $0.00.

How much cash does Enveric Biosciences have on hand?

Enveric Biosciences reported $4.91M in cash and cash equivalents in its most recent financial results.

What is Enveric Biosciences’s dividend yield?

Enveric Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services